High-value compounds from the molluscs of marine and estuarine ecosystems as prospective functional food ingredients: An overview

K Chakraborty, M Joy - Food Research International, 2020 - Elsevier
Extensive biodiversity and availability of marine and estuarine molluscs, along with their
their wide-range of utilities as food and nutraceutical resources developed keen attention of …

Molluscan biological and chemical diversity: Secondary metabolites and medicinal resources produced by marine molluscs

K Benkendorff - Biological Reviews, 2010 - Wiley Online Library
The phylum Mollusca represents an enormous diversity of species with eight distinct
classes. This review provides a taxonomic breakdown of the published research on marine …

Development of highly stabilized curcumin nanoparticles by flash nanoprecipitation and lyophilization

SF Chow, KY Wan, KK Cheng, KW Wong… - European Journal of …, 2015 - Elsevier
The influence of critical operating parameters on the Flash Nanoprecipitation (FNP) and
resulting material properties of curcumin (CUR) nanoparticles has been evaluated using a …

[HTML][HTML] Sepia Ink Oligopeptide Induces Apoptosis in Prostate Cancer Cell Lines via Caspase-3 Activation and Elevation of Bax/Bcl-2 Ratio

F Huang, Z Yang, D Yu, J Wang, R Li, G Ding - Marine drugs, 2012 - mdpi.com
Sepia ink oligopeptide (SIO) is a tripeptide extracted from Sepia ink. To test the hypothesis
that SIO inhibits prostate cancer by inducing apoptosis, the effects of SIO on the proliferation …

Anticancer activity of an oligopeptide isolated from hydrolysates of Sepia ink

D Guo-Fang, FF HUANG, Y Zui-Su, YU Di… - Chinese Journal of …, 2011 - Elsevier
Aim To investigate the antitumor effect of peptides from Sepia ink by enzymatic hydrolysis.
Methods Sepia ink was hydrolyzed with trypsin to prepare peptides; hydrolysates were …

Self-assembling nanoparticles of dually hydrophobic prodrugs constructed from camptothecin analogue for cancer therapy

Y Zhang, R Yin, G Wu, M Yu, J Liu, X Wang… - European Journal of …, 2020 - Elsevier
Nanomedicines have shown success in cancer therapy in recent years because of their
excellent solubility in aqueous solution and drug accumulation through controlled release in …

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

RD Baird, J Kitzen, PA Clarke, A Planting… - Molecular cancer …, 2009 - AACR
A dose-escalation, phase I study evaluated the safety, pharmacokinetics,
pharmacogenomics, and efficacy of ES-285, a novel agent isolated from a marine mollusc …

Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies

P Schöffski, H Dumez, R Ruijter, B Miguel-Lillo… - Cancer chemotherapy …, 2011 - Springer
Purpose Spisulosine is a marine compound that showed antitumor activity in preclinical
studies. We report results of a phase I trial performed in patients with advanced solid tumors …

[PDF][PDF] Homospisulosine induced apoptosis in cervical carcinoma cells is associated with phosphorylation of Bcl-2 and up-regulation of p27/Kip1

MB Pilátová, N Nosálová, G Ockajakova… - Journal of Applied …, 2023 - jab.zsf.jcu.cz
Abstract Spisulosine (1-deoxysphinganine) is a sphingoid amino alcohol isolated from the
sea clams that showed potent antiproliferative activity against a broad spectrum of solid …

A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors

E Vilar, V Grünwald, P Schöffski, H Singer… - Investigational new …, 2012 - Springer
Summary Background ES-285 (Spisulosine) is a novel marine compound with antitumor
activity in preclinical studies. A phase I study was performed in patients with advanced solid …